<DOC>
	<DOCNO>NCT00511303</DOCNO>
	<brief_summary>This Phase II , open-label , multi-center trial design primarily evaluate rate complete major cytogenetic response STI571 demonstrate decrease percentage Ph chromosome positive cell bone marrow , patient CML refractory intolerant interferon-alpha . During core phase study , patient receive daily oral administration STI571 dose 400 mg , 12 month . After complete 12 month therapy patient may eligible receive additional therapy provide , opinion investigator , patient benefit treatment STI571 absence safety concern . Patients receive STI571 outpatient basis . During extended phase ( indefinite duration ) , patient may continue STI571 either progression accelerate phase , blast phase , death , development intolerable toxicity , investigator feel longer patient 's best interest continue therapy , whichever come first . The number visit reduce frequency . Patients discontinue study drug follow survival 5 year . STI571 consider active interferon-refractory patient population satisfies target achieve complete major response rate least 30 % , within preset error limit . Cytogenetic response evaluate every three month categorize either complete ( 0 % Ph+ chromosome cell ) , major ( 1 35 % Ph+ chromosome cell ) response . STI571 discontinue patient whose disease progress either accelerated phase blast crisis . A minimum 100 patient interferon refractory receive STI571 administer dose 400 mg day . In addition , protocol also open patient intolerant interferon-alpha order get preliminary evaluation response STI571 therapy . Up 100 intolerant patient enrol . Enrollment intolerant patient cease 100 , whenever 100 refractory patient accrue , whichever come first .</brief_summary>
	<brief_title>Protein-Tyrosine Kinase Inhibitor ( STI571 ) Treatment Patients With Ph+ Chronic Myeloid Leukemia</brief_title>
	<detailed_description>This Phase II trial evaluate least 100 patient rate complete major cytogenetic response STI571 demonstrate decrease percentage Ph chromosome positive cell bone marrow patient CML refractory intolerant interferon-alpha . Statistical consideration base refractory patient population . Intolerant patient include long recruitment refractory patient ongoing , maximum 100 intolerant patient , whichever come first .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>1 . Male female patient * 18 year age . 2 . Patients Ph chromosome positive CML chronicphase disease . 3 . Patients must document resistance interferonalpha contain therapy , define follow : 1 . Hematologic Resistance Failure achieve complete hematologic response , last least 1 month despite 6 month interferonalpha contain regimen . 2 . Cytogenetic Resistance Bone marrow cytogenetics show *65 % Ph chromosome positivity least one year interferonalpha base therapy 3 . Cytogenetic Refractoriness An increase Ph+ chromosome bone marrow cell least 30 percentage point ( eg. , 20 % 50 % , 30 % 60 % ) confirm two sample least 1 month apart , increase * 65 % 4 . Hematologic Refractoriness A rise WBC count ( *100 % increase level *20 x 109/L confirm two sample take least two week apart ) receive interferonalpha contain regimen . 4 . Patients demonstrate intolerance interferonalpha therapy define : document * Grade 3 nonhematologic toxicity ( grade 2 case neurologic neuropsichiatric toxicity ) , persist 2 week , patient receive interferonalpha contain regimen . Patients intolerant interferonalpha must 3 month time diagnosis . 5 . Written voluntary inform consent . 1 . Patients childbearing potential without negative pregnancy test prior initiation study drug . Barrier contraceptive precaution use throughout trial sex . 2 . Serum bilirubin creatinine concentration twice upper limit normal range . 3 . SGOT SGPT twice upper limit normal range . 4 . Percentage blast , basophils peripheral blood bone marrow &gt; 15 % . 5 . Percentage blast plus promyelocytes peripheral blood bone marrow ( 30 % . 6 . Patients platelet count &lt; 100 x 109/L 7 . Patients ECOG Performance Status Score * 3 . 8 . Patients receive busulfan within 6 week Visit 1 . 9 . Patients receive treatment interferonalpha within 14 day Visit 1 . 10 . Patients receive treatment cytosine arabinoside within 14 day Visit 1 . 11 . Patients receive treatment hydroxyurea within 7 day Visit 1 . 12 . Patients receive investigational agent within 28 day Visit 1 . 13 . Patients Grade 3/4 cardiac problem define New York Heart Association Criteria . 14 . Patients history noncompliance medical regimen consider potentially unreliable . 15 . Patients likely submit transplantation procedure study period ( 12 month )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Philadelphia chromosome</keyword>
	<keyword>protein-tyrosine kinase</keyword>
</DOC>